Fabio Fulfaro

Assistant Professor

Assistant Professor, Discipline Chirurgiche, Oncologiche e Stomatologiche

https://orcid.org/0000-0003-0875-8580

Emailfabio.fulfaro@unipa.it

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Fabio Fulfaro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

67 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

2699 Citations
30 h-Index
67 Article
30 Other
29 Other contribution
6 Chapter
More
- 1 Comment/debate

Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis
Galvano, A., Graceffa, G., Barraco, N., Fulfaro, F., Gristina, V., Bazan, V., Bono, M., Brunetti, O., Gori, S. & Silvestris, N., 2020, In: Cancers. 12, p. 1-14 14 p.
Research output: Contribution to journal › Article › peer-review
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Bazan, V., Fulfaro, F., Badalamenti, G., Russo, A., Fanale, D., Incorvaia, L., Swayden, M., Vincenzi, B., Iovanna, J. L., Olive, D. & Terruso, L., 2019, In: Therapeutic Advances in Medical Oncology. 11, p. 175883591984887- 15 p.
Research output: Contribution to journal › Article › peer-review
6 Citations (Scopus)
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
Galvano, A., Fulfaro, F., Taverna, S., Passiglia, F., Badalamenti, G., Incorvaia, L., Russo, A., Bazan, V., Barraco, N., Duro, G., Vincenzi, B., Tagliaferri, P., Beretta, G. & Duro, G., 2019, In: Therapeutic Advances in Medical Oncology. 11, 15 p.
Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus)
Isolated Metachronous Splenic Metastasis from Colon Cancer: Possible Explanations for This Rare Entity
Calamia, S., Fulfaro, F., Grassi, N., Cipolla, C., Rizzo, F., Calamia, S., Mingoia, G., Fulfaro, F., Grassi, N., Cipolla, C., Rizzo, F. & Mingoia, G., 2019, In: Journal of Gastrointestinal Cancer. 50, p. 143-146 4 p.
Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus)
Γ δ T Cell-Based Immunotherapy in Melanoma: State of the Art
Meraviglia, S., Pirrello, R., Cordova, A., Rinaldi, G., Toia, F., Lo Presti, E., Fulfaro, F., Di Stefano, A. B. & Dieli, F., 2019, In: Journal of Oncology. 2019, 8 p.
Research output: Contribution to journal › Article › peer-review

1 Finished
4 Active

Fabio Fulfaro

Fingerprint

Network

Dive into details

Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis

Isolated Metachronous Splenic Metastasis from Colon Cancer: Possible Explanations for This Rare Entity

Γ δ T Cell-Based Immunotherapy in Melanoma: State of the Art

Studio clinico randomizzato di fase III per valutare l’efficacia e la tollerabilità di un trattamento integrato (dietetico, farmaco-nutrizionale e farmacologico) in pazienti neoplastici con anoressia/cachessia e stress ossidativo correlati al cancro.

Analisi dei polimorfismi genici e dei microRNA come fattori predittivi di risposta agli inibitori delle tirosin-chinasi (TK) e dell’ angiogenesi nel trattamento dei tumori gastrointestinali stromali (GIST)

Studio di fase II sull’utilizzo di Docetaxel settimanale + Capecitabina metronomica come prima linea chemioterapica in pazienti con Carcinoma gastrico metastatico con basso performance status: correlazione tra risposta al trattamento ed espressione di VEGF.

Profili molecolari nel carcinoma della mammella maschile (Male Breast Cancer, MBC)